

# Gennaro Sardella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5244104/publications.pdf>

Version: 2024-02-01

26  
papers

1,212  
citations

566801

15  
h-index

580395

25  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1634  
citing authors

#	ARTICLE	IF	CITATIONS
1	Next-generation balloon-expandable Myval transcatheter heart valve in low-risk aortic stenosis patients. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 889-895.	0.7	14
2	Optical coherence tomography, intravascular ultrasound or angiography guidance for distal left main coronary stenting. The <sc>ROCK</sc> cohort <sc>II</sc> study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 664-673.	0.7	20
3	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
4	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). <i>American Journal of Cardiology</i> , 2022, 172, 73-80.	0.7	4
5	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E704-E715.	0.7	8
6	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1143-1150.	0.7	1
7	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <sc>TAVI</sc> for severe aortic stenosis: Insights from the <sc>WIN-TAVI</sc> registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 516-526.	0.7	17
8	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	0.7	7
9	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1032.	3.0	27
10	Impact of High Body Mass Index on Vascular and Bleeding Complications After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 155, 86-95.	0.7	12
11	Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Cardiovascular Interventions. 2020, 96, 1156-1171.	0.7	2
12	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2020, 125, 441-448.	0.7	9
13	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
14	Efficacy and Safety of ProGlide Versus Prostar XL Vascular Closure Devices in Transcatheter Aortic Valve Replacement: The RISPEVA Registry. <i>Journal of the American Heart Association</i> , 2020, 9, e018042.	1.6	30
15	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's International Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 198-207.	0.7	13
16	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	1.2	60
17	Ticagrelor With or Without Aspirin After Complex-PCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	1.2	122
18	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	0.7	35

#	ARTICLE	IF	CITATIONS
19	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 1124-1131.	0.7	22
20	A sentinel in Mitraclip intervention: Catch the enemy!. Catheterization and Cardiovascular Interventions, 2019, 93, E346-E348.	0.7	1
21	Comparison of ProGlide vs. Prostar in patients undergoing transcatheter aortic valve implantation. Minerva Cardioangiologica, 2019, 67, 443-449.	1.2	22
22	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1-12.	1.1	77
23	Acute and 30-Day Outcomes in Women After TAVR. JACC: Cardiovascular Interventions, 2016, 9, 1589-1600.	1.1	85
24	Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent) Trial. Overlock 10, Jf 50 542 International Journal of Cardiology, 2016, 207, 168-176.	0.8	22
25	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2860-2868.	1.2	116
26	Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2014, 64, 2086-2097.	1.2	388